28 February 2024 - Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the US, France, Germany, and Italy, two medical oncology societies, and a drug bulletin. 

All retrieved ratings were recategorised using a four point ranking scale to indicate negative or non-quantifiable, minor, substantial, or major added benefit.

131 oncology drugs with 166 indications were evaluated for their added benefit by at least one organisation within the required timeframe, yielding a total of 458 added benefit ratings; 189 (41%) were negative or non-quantifiable.

Read BMJ article